An interventional study of Accelerated rTMS treatment in Major Depressive Disorder (MDD), sponsored by NeuroQore Inc.. Completed at 1 site in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by NeuroQore Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 755th largest by enrollment of the 1,323 interventional ones that give a count, is one of 69 that started in 2025, is one of 472 with no phase, and was the 1,368th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
University of Kentucky · Sites in United States
Ages 18–75
Eli Lilly and Company · Sites in United States, Bulgaria, Hungary and 5 more countries
Ages 18–75
Alkermes, Inc. · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 22 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 69 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 585 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
NeuroQore Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
NeuroQore Inc. has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
98 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions.
The goal of this clinical trial is to evaluate the safety and effectiveness of an accelerated but shortened TMS dosing regimen for adults with MDD aged 22-85.
Participants in this study will be subjected to the same 19-minutes treatment session, but three times on the same day, and only for one day. This will greatly reduce the logistical burden of completing the therapy regime.
Study Description:
This single center, open label study will evaluate the safety and efficacy of accelerating the delivery of the NeuroQore TMS system's rectangular waveform rTMS protocol for the treatment of adults with MDD aged 22-85.
Currently cleared protocol with the FDA (the Standard of Care Protocol) is one 19-min treatment session a day for 5 days/week for 6 weeks. The accelerated protocol will involve the same 19-min treatment session offered three times in a single day, with no additional treatment sessions.
Primary Objectives:
Endpoints:
Primary
Study Population:
Men and women 22-85 with MDD that have failed one medication in the current episode.
Study Intervention:
NeuroQore TMS System includes (1) a pulse generator, (2) a magnetic coil, (3) a coil cooler, and (4) a chair with a headpiece. It has been cleared for clinical use (K232688) by the FDA for the treatment of MDD using a 19-min Standard of Care protocol.
Treatment during this study will be administered according to this protocol and following the instructions in the device user manual. Personalized stimulation targets will be produced from participants' structural MRI via the proprietary targeting generation component of the NeuroQore TMS system.
Only personnel trained and certified by NeuroQore will be permitted to administer treatment. All session and device information will be captured on appropriate data collection forms.
Study Duration:
The study is anticipated to last up to 6 months including enrollment and follow-up. Individual participant duration in the study will be 1 day of treatment, 24-hour and 7-day follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 Day x 3 Sessions treatment protocol, with 60 minutes rest between sessions. Each session is a 19-minutes rTMS treatment.
Device: Accelerated rTMS treatment
1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The MADRS is a 10-item clinician-rated scale; total score ranges from 0 to 60, with higher scores indicating more severe depression (worse outcome).
Time frame: Baseline (treatment day, pre-treatment) and 7 days post-treatment
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment
Change in Patient Health Questionnaire-9 (PHQ-9) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The PHQ-9 is a 9-item self-report scale; total score ranges from 0 to 27, with higher scores indicating more severe depression (worse outcome).
Time frame: Baseline (treatment day, pre-treatment) and 7 days post-treatment
Participants were recruited from January to April 2025 at a single community outpatient mental health clinic (LGTC Group, San Jose, California) offering rTMS treatment.
| Milestone | Accelerated Protocol |
|---|---|
| Started | 53 |
| Completed | 50 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Device malfunction delayed a session; participant chose to discontinue | 1 |
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The MADRS is a 10-item clinician-rated scale; total score ranges from 0 to 60, with higher scores indicating more severe depression (worse outcome).
| units on a scale | Accelerated Protocol |
|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment | 25.5 ± 5.4 |
Change in Patient Health Questionnaire-9 (PHQ-9) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The PHQ-9 is a 9-item self-report scale; total score ranges from 0 to 27, with higher scores indicating more severe depression (worse outcome).
| units on a scale | Accelerated Protocol |
|---|---|
| Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment | 8.5 ± 5.6 |
Collected over From the start of treatment through 7 days post-treatment (protocol follow-up); naturalistic clinic follow-up to 90 days post-treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Accelerated Protocol | 0/53 (0%) | 0/53 (0%) | 3/53 (5.7%) |
| Event | Accelerated Protocol |
|---|---|
| Application site pain (facial/scalp pain during stimulation)General disorders | 3/53 |
Modified intent-to-treat population: all 53 participants who started treatment.
| Age, Continuous(years) | Accelerated Protocol |
|---|---|
| Mean | 46.5 ± 14.7 |
| Sex: Female, Male(Participants) | Accelerated Protocol |
|---|---|
| Female | 35 |
| Male | 18 |
| Race/Ethnicity, Customized(Participants) | Accelerated Protocol |
|---|---|
| White, not Hispanic or Latino | 43 |
| Asian | 7 |
| Region of Enrollment(participants) | Accelerated Protocol |
|---|---|
| United States | 53 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data will not be made available to other researchers; participant consent under HIPAA and California privacy law did not include external data sharing. Aggregate results are posted on ClinicalTrials.gov and published (Goodman MS et al., Neuromodulation 2026, doi:10.1016/j.neurom.2026.05.007).
Ran from Jan 2025 to primary completion in May 2025, 3 months.
Results were first posted in Nov 2026, 1 year 6 months after primary completion.
Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 3 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NeuroQore Inc.